HRID2172176

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C

HCID44146842

Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1)

C34H59N9O12

PRODUCTS

生成物

结构：CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C

HCID9810532

Larazotide

C32H55N9O10

AUXILIARIES

试剂、催化剂与溶剂

溶剂HCID962

Water

H2O

PROCEDURE

实验过程

Solubilities of Larazotide acetate and the corresponding chloride salt in water were tested at 20° C. after 14 hours of vigorous stirring in the presence of residual solid. Concentrations of peptide are measured by standardized HPLC. The chloride salt is more soluble than the acetate salt.

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-1796805bfe664afeab2f1b5ea3d417a8
来源数据集: uspto-grants-2015_06
DOI: 10.6084/m9.figshare.5104873.v1
专利: US09051349B2
来源说明: uspto-grants-2015_06

反应 SMILES

[CH3:1][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:42])[CH3:41])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:12])[CH3:11])=[O:7])[CH3:3].CC(O)=O>O>[CH3:3][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:41])[CH3:42])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:11])[CH3:12])=[O:7])[CH3:1]